The use of radioligands with the ability to bind to PSMA makes molecular imaging a promising approach for both the diagnosis of prostate cancer and the selection of patients for PSMA-targeting radionuclide therapy. This evidence concerns the gene FOLH1 and Familial prostate cancer.